Subscribe for great stories in your community!
In the less than two months since becoming the first drug developer to receive Food and Drug Administration clearance for a NASH treatment, Madrigal Pharmaceuticals…
Later this week, the U.S. Food and Drug Administration is expected to make a decision on Madrigal Pharmaceuticals’ experimental NASH treatment, writes John George…
Conshohocken-based Madrigal Pharmaceuticals is in a flurry of activity as it prepares for the potential launch of its NASH drug candidate, writes John George…
A Conshohocken-based pharmaceutical company’s treatment for nonalcoholic steatoheptatitis (NASH) a severe form of liver disease, is getting priority review by the Food &…
Currently there is no U.S. Food and Drug Administration-approved medicine for nonalcoholic steatohepatitis, also referred to as NASH.
NASH is a fatty liver…
One Montgomery County company found its place on the list of seven best-paying biopharma companies in the nation where workers can take home over…
Conshohocken-based Madrigal Pharmaceuticals saw its shares leap in value after the company reported additional positive late-stage clinical trial data for its experimental non…
Madrigal Pharmaceuticals, West Conshohocken, has experienced a rapid rise in its stock price and market capitalization, which at the start of the week was at…
Before we send you to this site, please subscribe to our daily newsletter.
